Back to top
more

Zynerba Pharmaceuticals, Inc. (ZYNE)

(Delayed Data from NSDQ)

$11.45 USD

11.45
2,372,198

+0.35 (3.15%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.45 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ZYNE]

Reports for Purchase

Showing records 1 - 20 ( 119 total )

Industry: Medical - Generic Drugs

Record: 1

08/15/2023

Company Report

Pages: 5

Zynerba Sold Given Market Liquidity Constraints; We Project CVR Upside From Here, But Downgrade to Neutral on Deal

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 2

01/18/2022

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 3

01/05/2022

Company Report

Pages: 9

2H23 FXS Pivotal Data on Track; Taking Autism Forward Into Phase 3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 4

11/18/2021

Company Report

Pages: 6

3Q21: Zygel FXS Phase 3 Data Still Expected 2H23; Color on Other Potential Indications by Year End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 5

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ZYNE

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 6

09/21/2021

Company Report

Pages: 6

Zygel Enriched FXS Phase 3 Re-do Started; Other Indication Clarity By Year-End

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 7

05/13/2021

Company Report

Pages: 7

1Q21 Recap - RECONNECTING the Dots

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 8

05/13/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 9

05/06/2021

Company Report

Pages: 7

FXS Phase 3 Redo Design Suggests FDA Accommodating; 2023 Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 10

03/10/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 11

03/10/2021

Company Report

Pages: 7

4Q20 Recap - FDA Meeting for FXS in 1H21; Cash Runway Extended

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 12

12/21/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 13

12/21/2020

Company Report

Pages: 10

FXS Delayed Over Two Years as FDA Rebuffs Long-Shot Bid for NDA Filing on Post Hoc Data; PT Lower to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 14

12/18/2020

Company Report

Pages: 7

Confirmatory Trial Needed for FXS

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 15

11/10/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 16

11/10/2020

Company Report

Pages: 9

3Q20: Crucial Clarity From FDA in 4Q on Zygel Path Forward in FXS; Could Be Major Upside Surprise; Reiterate

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 17

11/09/2020

Company Report

Pages: 7

3Q20 Recap - FDA Update (FXS) Looms in 4Q20 as Significant Catalyst

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 18

08/19/2020

Company Report

Pages: 10

2Q20: Potential Near-Term Clarity for Zygel Path Forward in FXS and DEE; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 19

08/11/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 20

08/10/2020

Company Report

Pages: 7

2Q20 Recap - Regulatory Meetings Upcoming

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party